X
[{"orgOrder":0,"company":"Epsilogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epsilogen Limited Announces Interim phase 1 MOv18 IgE data presented at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Kings College London","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Epsilogen Licences Experimental Ige Antibody from KCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Epsilogen Announces Further Uk Government Funding for Further Development of A Novel Ig E Antibody Cancer Immunotherapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","amount":"$41.2 million","upfrontCash":"Undisclosed","newsHeadline":"Epsilogen Announces Completion of Oversubscribed \u00a330.75 Million ($41.20 Million) Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Epsilogen
Filters
Companies By Therapeutic Area
Details:
The proceeds from the financing will enable Epsilogen to establish clinical proof of concept for lead drug candidate MOv18 IgE in a phase Ib trial in platinum-resistant ovarian cancer, an aggressive cancer with poor treatment alternatives.
Lead Product(s):
MOv18 IgE
Therapeutic Area: Oncology
Product Name: MOv18 IgE
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Novartis Venture Fund
Deal Size: $41.2 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
March 02, 2022
Details:
Epsilogen will collaborate with King’s College London (KCL) and use the funding from the grant to further develop the company’s novel cancer immunotherapeutic EPS 201.
Lead Product(s):
EPS 201
Therapeutic Area: Oncology
Product Name: EPS 201
Highest Development Status: IND Enabling
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Innovate UK
Deal Size: $1.3 million
Upfront Cash: Undisclosed
Deal Type: Funding
October 21, 2020
Details:
MOv18 IgE, at the doses administered, was found to be well tolerated in almost all patients, with urticaria1 being the most frequently observed adverse event.
Lead Product(s):
MOv18 IgE
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 27, 2020
Details:
The antibody developed at KCL in collaboration with Cancer Research UK is the first therapeutic IgE antibody to enter clinical trials.
Lead Product(s):
MOv18 IgE
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Recipient:
Kings College London
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
April 21, 2020